Targeted proteomics for cancer biomarker verification and validation.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2022-04-18 DOI:10.3233/cbm-210218

Seiryo Ogata, Takeshi Masuda, S. Ito, S. Ohtsuki

{"title":"Targeted proteomics for cancer biomarker verification and validation.","authors":"Seiryo Ogata, Takeshi Masuda, S. Ito, S. Ohtsuki","doi":"10.3233/cbm-210218","DOIUrl":null,"url":null,"abstract":"Targeted proteomics is a method that measures the amount of target proteins via liquid chromatography-tandem mass spectrometry and is used to verify and validate the candidate cancer biomarker proteins. Compared with antibody-based quantification methods such as ELISA, targeted proteomics enables rapid method development, simultaneous measurement of multiple proteins, and high-specificity detection of modifications. Moreover, by spiking the internal standard peptide, targeted proteomics detects the absolute amounts of marker proteins, which is essential for determining the cut-off values for diagnosis and thus for multi-institutional validation. With these unique features, targeted proteomics can seamlessly transfer cancer biomarker candidate proteins from the discovery phase to the verification and validation phases, thereby resulting in an accelerated cancer biomarker pipeline. Furthermore, understanding the basic principles, advantages, and disadvantages is necessary to effectively utilize targeted proteomics in cancer biomarker pipelines. This review aimed to introduce the technical principles of targeted proteomics for cancer biomarker verification and validation.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3233/cbm-210218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Targeted proteomics is a method that measures the amount of target proteins via liquid chromatography-tandem mass spectrometry and is used to verify and validate the candidate cancer biomarker proteins. Compared with antibody-based quantification methods such as ELISA, targeted proteomics enables rapid method development, simultaneous measurement of multiple proteins, and high-specificity detection of modifications. Moreover, by spiking the internal standard peptide, targeted proteomics detects the absolute amounts of marker proteins, which is essential for determining the cut-off values for diagnosis and thus for multi-institutional validation. With these unique features, targeted proteomics can seamlessly transfer cancer biomarker candidate proteins from the discovery phase to the verification and validation phases, thereby resulting in an accelerated cancer biomarker pipeline. Furthermore, understanding the basic principles, advantages, and disadvantages is necessary to effectively utilize targeted proteomics in cancer biomarker pipelines. This review aimed to introduce the technical principles of targeted proteomics for cancer biomarker verification and validation.

查看原文本刊更多论文

靶向蛋白质组学用于癌症生物标志物的验证和验证。

靶向蛋白质组学是一种通过液相色谱-串联质谱法测量靶蛋白数量的方法，用于验证和验证候选癌症生物标志物蛋白。与ELISA等基于抗体的定量方法相比，靶向蛋白质组学能够快速开发方法，同时测量多种蛋白质，并具有高特异性的修饰检测。此外，通过对内部标准肽进行标记，靶向蛋白质组学检测标记蛋白的绝对数量，这对于确定诊断的临界值以及多机构验证至关重要。凭借这些独特的功能，靶向蛋白质组学可以无缝地将癌症生物标志物候选蛋白从发现阶段转移到验证和验证阶段，从而加速癌症生物标志物管道。此外，了解靶向蛋白质组学的基本原理、优缺点是有效利用癌症生物标志物管道的必要条件。本文旨在介绍靶向蛋白质组学在癌症生物标志物鉴定和验证中的技术原理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464